New data from clinical and preclinical oncology programs to be presented Preliminary Phase 1 data from anti-COVID-19 candidate MP0420 (ensovibep) expected Zurich-Schlieren, Switzerland, December 02, 2020.   Molecular Partners AG  (SIX: MOLN), a clinical-stage biotech company that is developing a

Zurich-Schlieren, Switzerland, November 30, 2020.   Molecular Partners AG  (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that Dr. Patrick Amstutz, CEO of Molecular Partners, will participate

Zurich-Schlieren, Switzerland, November 23, 2020.   Molecular Partners AG  (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that a first cohort of eight healthy volunteers has been dosed in a

Zurich-Schlieren, Switzerland, October 29, 2020.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced today its interim management statement for the period ending September30, 2020.

Novartis has been granted an option to in-license global rights of MP0420 and MP0423 – multi-targeted direct-acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-19 MP0420 and MP0423 are potential medicines with a unique approach for both the prevention and

DARPin® candidates demonstrate 100% survival in an aggressive viral challenge model Data support utility of anti-COVID-19 DARPin® candidates as potent therapeutics First-in-human clinical trial initiation of MP0420 planned for November 2020 Zurich-Schlieren, Switzerland, October 6, 2020.

MP0317 activates multiple antitumor immune cell types in vitro when in the presence of tumor stroma associated FAP MP0317 mouse surrogate localizes to FAP-expressing tumors and induces strong and durable anti-tumor responses without systemic toxicity, and demonstrates strong anti-tumor immune

High yields in bacterial fermentation systems support ability of DARPin® manufacturing to rapidly scale for global supply First and only, tri-specific antiviral demonstrating potential best-in-class potency in vivo First-in-human clinical trial initiation planned for November 2020 Zurich-Schlieren,

Zurich-Schlieren, Switzerland, September 11, 2020.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built proteins known as DARPin® therapeutics, today announced that Patrick Amstutz, chief executive officer, will be presenting at the HC

Research & Development: Developed novel anti-COVID-19 multi-specific DARPin® candidates, of which MP0420 is being prepared for clinical trial initiation in Q4 2020. Initial  in vitro  and  in vivo  data highly supportive of unique mechanisms of action with ultra-potent anti-viral activity seen.